查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球T细胞淋巴瘤市场 - 2023-2030年
市场调查报告书
商品编码
1289780

全球T细胞淋巴瘤市场 - 2023-2030年

Global T-Cell Lymphoma Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

T细胞淋巴瘤市场在2022年达到14.852亿美元，预计到2030年将见证有利可图的增长，达到27.878亿美元。在预测期间（2023-2030年），T细胞淋巴瘤市场预计将呈现8.4%的复合年增长率。

T细胞淋巴瘤分为两种类型：外周T细胞淋巴瘤和T细胞淋巴细胞淋巴瘤。T细胞淋巴瘤可通过化疗、放疗、免疫疗法、抗病毒药物治疗、干细胞移植和其他疗法进行治疗。

T细胞淋巴瘤市场的增长还归因于辐射导致的淋巴瘤癌症发病率的上升，T细胞淋巴瘤特异性疗法数量的增加，以及自身免疫性疾病导致的淋巴瘤风险。

市场动态

全球癌症患病率的增加

癌症患病率的增加是影响T细胞淋巴瘤市场机会的驱动因素之一。另一个因素是医疗基础设施投资的增加和老年人口的增加，导致T细胞淋巴瘤市场的扩大。

根据世卫组织的数据，癌症是全球死亡的主要原因，2020年将有近1000万人死亡，或近六分之一的死亡。每年约有40万名儿童患上癌症。最常见的癌症在各国之间有所不同。

治疗费用高，持续时间长

由于其独特的作用机制，T细胞淋巴瘤的治疗非常昂贵，收集和制造过程也增加了总成本。治疗的高额费用也因病人的疾病程度和根据病人标准所需的治疗水平而有所不同。

COVID-19影响分析

由于癌症治疗服务的中断和癌症治疗的临床试验的停止，COVID-19大流行对预测期内的全球T细胞淋巴瘤市场趋势产生了负面影响。

由于COVID-19的流行，皮肤淋巴瘤患者错过接受关键的诊断测试和治疗的风险增加，因为他们难以进入医院或缺乏可用的医疗资源。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按类型抽查
  • 按治疗方法分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 全球癌症发病率的增加
    • 限制因素
      • 成本高，治疗时间长
    • 机会
      • T细胞淋巴瘤市场的投资和研究资金的增加
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按药物类别划分

  • 周边T细胞淋巴瘤
  • 皮肤T细胞淋巴瘤
  • 无性大细胞淋巴瘤
  • 其他

第八章：按治疗方法分类

  • 放射治疗
  • 化学治疗
  • 靶向治疗
  • 手术治疗
  • 干细胞移植
  • 其他疗法

第九章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第十章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十一章 ：公司简介

  • Johnson & Johnson
  • Novartis AG
  • Bristol Myers Squibb Company
  • Merck & Co Inc
  • F.Hoffmann La Roche Ltd
  • Acrotech Biopharma
  • GlaxoSmithKline Plc
  • Spectrum Pharmaceuticals

第十二章 ：附录

简介目录
Product Code: PH1486

Market Overview

The T-Cell Lymphoma Market reached US$ 1,485.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,787.8 million by 2030. The T-cell lymphoma market is expected to exhibit a CAGR of 8.4% during the forecast period (2023-2030).

T-cell lymphoma is classified into two types: peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. T-cell lymphoma can be treated with chemotherapy, radiotherapy, immunotherapy, antiviral medication, stem cell transplantation, and other therapies.

The growth of the T-cell lymphoma market is also attributed to the rise in lymphoma cancer incidence due to radiation, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.

Market Dynamics

Increase in Prevalence of Cancer Worldwide

The increase in the prevalence rate of cancer is one of the drivers that affect the T Cell lymphoma market opportunities. Another factor is increasing investment in healthcare infrastructure and the rising geriatric population that leads to the expansion of the T-cell lymphoma market.

According to WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Each year, approximately 400,000 children develop cancer. The most common cancers vary between countries.

High Cost and Long Duration of Treatment

Treatment for T-cell lymphoma is very expensive because of its unique mechanism of action and the collections and manufacturing processes also add to the total costs. The high cost of the treatment also varies from patient to patient according to the level of disease and level of treatment required as per the patient standards.

COVID-19 Impact Analysis

The COVID-19 pandemic had a negative impact on the global T-cell lymphoma market trend over the projection period, owing to disruptions in cancer treatment services and the halt of clinical trials for cancer therapy.

Due to the COVID-19 epidemic, patients with cutaneous lymphomas were at an increased risk of missing receiving crucial diagnostic tests and treatments, either because hospitals were difficult for them to access or because of a lack of available healthcare resources.

Segment Analysis

The Chemotherapy Segment will Dominate the Market in the Forecast Period with around 40.8% Market Share

Chemotherapy is a common treatment for T-cell lymphoma because it inhibits and slows the proliferation of cancer cells. In addition to surgery and radiation therapy, chemotherapy can affect the entire body. These treatments can destroy or eliminate cancer cells in a specific area of the body.

Also, a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), or other multidrug regimens, is frequently used for treatment.

Geographical Analysis

North America is the Dominating Region During The Forecast Period Accounting For 42.4% In The Overall Market

The global T-cell lymphoma market is large in the North American region due to the high number of cases of T-cell lymphoma, the presence of strong rivals, and increased research in the North American region. Also, T-cell lymphomas are a subtype of Non-Hodgkin lymphoma and a rise in Non-Hodgkin lymphoma cases would likely increase the demand for new treatment options, assisting the market's growth.

Competitive Landscape

The major global players include: Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Merck & Co Inc, F.Hoffmann La Roche Ltd, Acrotech Biopharma, GlaxoSmithKline Plc, and Spectrum Pharmaceuticals.

  • Why Purchase the Report?
  • To visualize the global T-cell lymphoma market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global T-cell lymphoma market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global T-cell lymphoma market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in the prevalence of cancer worldwide
    • 4.1.2. Restraints
      • 4.1.2.1. High cost and long duration of treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Rise in the investments and research funding of T-cell lymphoma market
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Peripheral T Cell Lymphoma
  • 7.2. Cutaneous T Cell Lymphoma
  • 7.3. Anaplastic Large Cell Lymphoma
  • 7.4. Others

8. By Treatment

  • 8.1. Radiotherapy
  • 8.2. Chemotherapy
  • 8.3. Targeted Therapy
  • 8.4. Surgery
  • 8.5. Stem Cell Transplantation
  • 8.6. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1.1. The U.S.
      • 9.2.5.1.2. Canada
      • 9.2.5.1.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1.1. Germany
      • 9.3.5.1.2. The UK
      • 9.3.5.1.3. France
      • 9.3.5.1.4. Italy
      • 9.3.5.1.5. Spain
      • 9.3.5.1.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1.1. Brazil
      • 9.4.5.1.2. Argentina
      • 9.4.5.1.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1.1. China
      • 9.5.5.1.2. India
      • 9.5.5.1.3. Japan
      • 9.5.5.1.4. Australia
      • 9.5.5.1.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Johnson & Johnson
  • 11.2. Novartis AG
  • 11.3. Bristol Myers Squibb Company
  • 11.4. Merck & Co Inc
  • 11.5. F.Hoffmann La Roche Ltd
  • 11.6. Acrotech Biopharma
  • 11.7. GlaxoSmithKline Plc
  • 11.8. Spectrum Pharmaceuticals

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us